Oncotarget
The SCD1 Inhibitor Aramchol, Regorafenib, and Metformin Combine to Kill Uveal Melanoma Cells
2:12
BUFFALO, NY – March 31, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on March 27, 2026, titled “The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells.” Led by Michael R. Booth, Laurence Booth, and Jane L. Roberts from Virginia Commonwealth University, with corresponding author Paul Dent from the same institution and John M. Kirkwood…